Individual results may vary

"Your pain is real; it is valid, and you
don't have to go through it alone."
—Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

Individual results may vary

"Your pain is real; it is valid, and you
don't have to go through it alone."
—Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

Contact an Alnylam Patient Education Liaison (PEL)

Our Alnylam Patient Education Liaisons have backgrounds in nursing and are experienced in educating people and their families about matters related to acute hepatic porphyria (AHP). Request an Alnylam PEL to reach out to you and discuss questions you may have about AHP. Submitting a request is quick and easy—simply fill out the form below.

The purpose of the Alnylam PELs is to provide education to patients, their families, and caregivers. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team. PELs do not provide medical care or advice. All diagnosis and treatment decisions should be made by you and your doctor.

*Indicates required field

*First name

*Last name

*Street address

*City

*State

*ZIP/postal code

*Email address

*Phone

*Please confirm the type of information you would like a Patient Education Liaison to contact you about:

*I would like an Alnylam Patient Education Liaison to contact me with information about Acute Hepatic Porphyria (AHP).

*Please confirm the following so that we may contact you:

*I understand that the Alnylam PEL is not providing me medical advice and is not part of my healthcare team.

*I understand that Alnylam will use reasonable technical and organizational measures to protect the information I share with the PEL and will not use or disclose it outside of the company.

*By submitting this form, I agree to the Alnylam Privacy Policy, attest that I am 18 years or older and a US resident, and consent to the processing of my personal data per the terms outlined in the Data Privacy Notification and Consent.

Additional (optional) requests:

OK to leave voicemail.

I would also like Alnylam to contact my healthcare provider to discuss AHP. I understand that the Alnylam representative will not discuss my medical information or personal information with my healthcare provider.

*First name

*Last name

*Name of medical practice

*Street address

*City

*State

*ZIP/postal code

*Phone

IMPORTANT SAFETY INFORMATION

Do not use GIVLAARI^® (givosiran) if you have ever had a severe allergic reaction to GIVLAARI.

GIVLAARI can cause:

Severe allergic reaction

Tell your doctor or nurse right away if you experience any of the following signs or symptoms of a severe allergic reaction during treatment:
- Swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
- Breathing problems or wheezing
- Feeling dizzy or fainting
- Rash or hives
- Itching
If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.
Liver problems

Your doctor will check your liver function by doing blood tests:
- Before you start using GIVLAARI
- Once a month for the first 6 months of treatment
- And when they think it is needed
If these tests show abnormal results, your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.
Kidney problems

Your doctor will check how your kidneys are working while you are using GIVLAARI.
Injection site reactions

GIVLAARI is given as an injection under the skin (called a “subcutaneous injection”). Reactions to this injection may happen during treatment with GIVLAARI.

Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.
Increased blood homocysteine levels

GIVLAARI may cause increased levels of homocysteine (a type of amino acid) in your blood. Your doctor will check your homocysteine levels before and during treatment by doing blood tests. If your levels are increased, your doctor may check your folate, vitamins B12 and B6, and tell you to take a vitamin B6 supplement.
Inflammation of the pancreas (pancreatitis)

Cases of acute pancreatitis including some that were severe, have been reported in patients receiving GIVLAARI. If you have a severe case of acute pancreatitis your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

What are the common side effects of GIVLAARI?

The most common side effects of GIVLAARI are nausea and injection site reactions. These are not all the possible side effects of GIVLAARI. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-8 00-FDA -1088.

WHAT IS GIVLAARI?

GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.

For additional information about GIVLAARI, please see full Prescribing Information.

"Your pain is real; it is valid, and you don't have to go through it alone." —Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

"Your pain is real; it is valid, and you don't have to go through it alone." —Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

Contact an Alnylam Patient Education Liaison (PEL)

IMPORTANT SAFETY INFORMATION

"Your pain is real; it is valid, and you
don't have to go through it alone."
—Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

"Your pain is real; it is valid, and you
don't have to go through it alone."
—Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI